会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • イミン誘導体及びアミド誘導体
    • 内源性衍生物和酰胺衍生物
    • WO2005094805A1
    • 2005-10-13
    • PCT/JP2005/006464
    • 2005-04-01
    • 株式会社医薬分子設計研究所田中 りか北川 博久佐々木 正雄武藤 進板井 昭子徳山 竜光
    • 田中 りか北川 博久佐々木 正雄武藤 進板井 昭子徳山 竜光
    • A61K31/137
    • C07D209/30
    • A medicine having prostaglandin D2 (PGD2) production inhibitory activity and having as an active ingredient a substance selected from compounds represented by the general formula (I): A-Y-B {wherein A and B each independently represents an optionally substituted, cyclic hydrocarbon or heterocyclic group; and Y represents -CH=N-, -N=CH-, -CONH-, or -NHCO-, provided that the compounds represented by the following formula (I-1) [wherein X represents the formula -N=C(R )- (wherein the left-side bond is bonded to the benzene ring and the right-side bond is bonded to the nitrogen atom) or the formula -NH-CH(R )- (wherein the left-side bond is bonded to the benzene ring and the right-side bond is bonded to the nitrogen atom); R , R , R , and R each independently represents hydrogen, halogeno, or optionally substituted C1-6 alkyl or hydroxy; R represents an optionally substituted C1-6 alkyl or C6-10 aryl group; and R represents optionally substituted amino] are excluded}, salts, hydrates, and solvates.
    • 具有前列腺素D2(PGD2)生产抑制活性的药物,作为活性成分,选自通式(I)表示的化合物:A-Y-B {其中A和B各自独立地表示任选取代的环状烃或杂环基; 并且Y表示-CH = N-,-N = CH-,-CONH-或-NHCO-,条件是由下式(I-1)表示的化合物[其中X表示式-N = C(R 5) - (其中左侧键与苯环键合,右侧键键合到氮原子上)或式-NH-CH(R 5) - (其中左侧键与苯环键合, 侧键与苯环键合,右侧键与氮原子键合); R 1,R 2,R 3和R 4各自独立地表示氢,卤素或任选取代的C 1-6烷基或羟基; R 5表示任选取代的C 1-6烷基或C 6-10芳基; 和R表示任选取代的氨基]},盐,水合物和溶剂合物。